At the Global Brain Coalition’s Brain Days, which took place alongside the 81st United Nations General Assembly (UNGA81) during High-level Week, policymakers, scientists, clinicians, patient advocates and international organisations gathered to discuss how brain health can move higher up the global policy agenda.
The European Federation of Neurological Associations (EFNA), together with the European Academy of Neurology, have launched a survey to determine the impact of COVID-19 on neurology service delivery.
For November 2020, we have selected: Agarwal P. et al. Neurological manifestations in 404 COVID‑19 patients in Washington State. J Neurol 2020 Aug 6;1-3. doi: 10.1007/s00415-020-10087-z. Online ahead of print.
Together with medical societies from the Open Access Transition Working Group of the BioMed Alliance we published a statement on 5 October highlighting a series of concerns around Plan S.
For November 2020, we have selected: Wang Z. et al. Skin α-Synuclein Aggregation Seeding Activity as a Novel Biomarker for Parkinson Disease. JAMA Neurol 2020;e203311. doi: 10.1001/jamaneurol.2020.3311. Online ahead of print.
Dementia with Lewy bodies (DLB) is a neurodegenerative disorder characterised by fluctuating cognition, recurrent visual hallucinations, impairment of sleep (REM sleep behaviour disorder) and parkinsonism.
Factors influencing long term outcomes after elective surgical intervention remain poorly studied. One recent study (Lamberink et al., 2020) addressed this issue analysing the association between histopathology and seizure outcome and drug freedom up to 5 years after epilepsy surgery.
Newest addition to Breaking News submitted by Neurooncology Panel: Neuro-oncology Management During the COVID-19 Pandemic With a Focus on WHO Grade III and IV Gliomas
Newest contribution to Breaking News is by Dementia Panel: Tackling challenges in care of Alzheimer’s disease and other dementias amid the COVID-19 pandemic, now and in the future